DIAMOND
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure
INCLUSION Criteria
- LVEF<40% measured in the last 12 months
- NYHA class II- IV
- eGFR> 30 mL/min/1.73m² at Screening
- Hyperkalemia or hyperkalemia documented in the last 12 months with a subsequent dose decrease or discontinuation of one or more RAASI medications
- Hospitalization for HF within the last 12months
EXCLUSION Criteria
- symptomatic Hypotension
- significant primary aortic or mitral valvular heart disease
- heart transplantation or planned heart transplatation
- restrictive, constructive, hypertrophic cardiomyopathie
- NT-proBNP <500pg/mL
Ansprechpartner im Studienzentrum
Neurath,
Barbara
Leitung Studienambulanz (Geb. 24)
Dr.
Wachter,
Angelika
Stellv. Leitung Studienzentrum (Geb. 24)
